Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valsartan - Novartis

Drug Profile

Valsartan - Novartis

Alternative Names: CGP-48933; Diovan; Diovane; Kalpress; Miten; Nisis; Provas; Tareg; Valpression; Vals; Varexan

Latest Information Update: 31 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer ESTEVE; JW Pharmaceutical; Novartis; Zeneca Farma
  • Class Antihypertensives; Branched-chain amino acids; Cardiovascular therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
  • Discontinued Kidney disorders; Pulmonary fibrosis; Type 2 diabetes mellitus

Most Recent Events

  • 06 Jan 2020 No development reported - Phase-III for Hypertension (In children) in Spain, Poland, Lithuania, Italy, Hungary, Germany, France, Belgium, Brazil, Guatemala (PO)
  • 31 Aug 2019 Efficacy and adverse events data from a phase III trial in Hypertension, with or without chronic kidney disease presented at the Annual Congress of the European Society of Cardiology (ESC-2019)
  • 24 Jun 2018 Biomarkers information updated
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top